X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Under the terms of the agreement, upon close, Corza Health will acquire the assets and licenses that support the development and commercialization of TachoSil®, while Takeda will maintain ownership of the manufacturing facility in Linz, Austria.
Lead Product(s): Human Fibrinogen,Thrombin
Therapeutic Area: Hematology Product Name: TachoSil
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Corza
Deal Size: $427.0 million Upfront Cash: 427.0 million
Deal Type: Divestment September 16, 2020
Details:
In late March, EU antitrust regulators had expressed concern about the deal and opened a full investigation into it.
Lead Product(s): Human fibrinogen,Thrombin
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Termination April 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
